论文部分内容阅读
目的评价不同化疗途径对中晚期胰腺癌的治疗价值。方法对15例中晚期胰腺癌患者行单纯静脉化疗,15例行介入动脉化疗,15例行胃十二指肠动脉插管化疗;对患者的临床受益反应、客观疗效、不良反应以及生存期进行分析。结果三组病例的临床受益率分别为25.0%、61.5%和76.5%(P<0.05);有效率分别为33.3%、46.2%和64.7%(P>0.05);出现严重不良反应的病例分别为4例、2例和1例(P>0.05);中位生存时间分别为8.0、9.0和11.5个月(P<0.05)。结论行胃十二指肠动脉插管化疗可提高中晚期胰腺癌患者的临床受益率,疗效较好,并可延长患者生存期。
Objective To evaluate the therapeutic value of different chemotherapy on advanced pancreatic cancer. Methods Fifteen patients with advanced pancreatic cancer underwent simple intravenous chemotherapy, 15 received interventional arterial chemotherapy and 15 received gastroduodenal arterial intubation chemotherapy. Clinical benefit response, objective efficacy, adverse reactions, and survival were evaluated analysis. Results The clinical benefit rates of the three groups were 25.0%, 61.5% and 76.5% respectively (P <0.05), and the effective rates were 33.3%, 46.2% and 64.7% respectively (P> 0.05). The patients with serious adverse reactions were 4 cases, 2 cases and 1 case (P> 0.05). The median survival time was 8.0, 9.0 and 11.5 months respectively (P <0.05). Conclusions Gastro-duodenal arterial intubation chemotherapy can improve the clinical benefit rate of patients with advanced pancreatic cancer, which has a good curative effect and prolongs the survival time of patients.